The demand for coronary vaccines has declined sharply compared with the same period last year, Kangshino Biological Co., Ltd. is expected to lose more than 800 million last year (RMB, the same below, about S $ 156 million).
According to the surging news report, after the market (January 30) on Monday (January 30), Kangshino disclosed the 2022 annual results announcement announcement that it is expected to belong to the owner of the parent companyThere will be losses, the amount of losses will be 830 million yuan to 996 million yuan; the net profit loss of net profit after deducting non -recurring profit or loss of the parent company owner is 945 million yuan to 1.134 billion yuan.
For the cause of losses, Kangshino explained that during the reporting period, the market environment of the coronary vaccine at home and abroad in China has changed significantly.The growth rate has slowed down, and some areas showing a situation that is greater than the demand, market competition has continued to intensify, and the company's crown disease vaccine product sales revenue decreased significantly compared with the same period last year. At the same time, due to the continuous advancement of the commercialization processThe remediation of coronary vaccine -related inventory with signs of impairment has caused the company to lose money by the company's net profit attributable to the owner of the parent company.
Kangshino's official website information shows that Kangxino was founded in 2009 and focused on the research and development, production and commercialization of innovation, high -quality, and accessible vaccines.The listing products of Kangxino Biological include the only new Coronary virus vaccine (5 adenovirus carrier) Kwwissa, the world's first inhalation of coronary vaccine,Weisa Misty (5 adenovirus vector), China's first tetravass bin -combined vaccine ACYW135 group meningitis polysaccharide binding vaccine (CRM197 carrier) Man Haixin, China's first di197 di -valence brain bin -binding vaccine using CRM197 carrierA group C group meningitis polysaccharide combined vaccine (CRM197 carrier) Minai and so on.
